A Model for Achieving Comprehensive Biomarker Testing in Non–Small Cell Lung Cancer

Lung cancer accounts for almost 25% of all cancer deaths in the United States, with non–small cell lung cancer representing 85% of all lung cancer diagnoses.1 However, the 5-year survival rate for patients with lung cancer has increased from 21% in 2014 to 25% in 2018.2 While some of the improved survival rate can be attributed to a decrease in smoking rates and an uptick in preventive lung cancer screenings, the largest contributing factor is novel biomarker targeted therapies in the subset of patients with metastatic non–small cell lung cancer. For patients who are diagnosed with metastatic non–small cell lung cancer, it is imperative to order and collect comprehensive biomarker testing to determine what the optimal treatment will be, as this practice has “proven to help people with lung cancer live longer with a better quality of life.” 8 Biomarker Real-World Studies In examining OHC's data and the impact on patient care, we knew that all patients with advanced non–small cell lung cancer should have received testing. Cycle 2 of the quality initiative study was a newly designed Non-Small Cell Lung Cancer Initial Consult Note template in our electronic health record (EHR), McKesson's iKnowMed Generation 2 (G2).13 This new note contained all the primary initial consult note components but also included NCCN guidelines for non–small cell